ELI LILLY AND COMPANY Payments for (Proceeds from) Short-term Investments
ELI LILLY AND COMPANY (LLY) reported Payments for (Proceeds from) Short-term Investments of $112.20 million for the 12-month period ending 2018-12-31, per its 8-K filed 2019-10-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromShortTermInvestments · last filed 2019-10-24
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for the quarter ending 2012-12-31 was $2.43B, a 6.69% decline year-over-year.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for the quarter ending 2012-09-30 was $351.40M.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for the quarter ending 2012-06-30 was -$151.10M, a 855.50% decline year-over-year.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for the quarter ending 2012-03-31 was -$457.60M.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for fiscal 2015 was $842.20M, a 48.58% decline from fiscal 2014.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for fiscal 2014 was $1.64B, a 6.98% increase from fiscal 2013.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for fiscal 2013 was $1.53B, a 29.52% decline from fiscal 2012.
- ELI LILLY AND COMPANY payments for (proceeds from) short-term investments for fiscal 2012 was $2.17B, a 5.52% increase from fiscal 2011.
| Period end | Payments for (Proceeds from) Short-term Investments 3 month | Payments for (Proceeds from) Short-term Investments 6 month | Payments for (Proceeds from) Short-term Investments 6 month as first filed | Payments for (Proceeds from) Short-term Investments 9 month | Payments for (Proceeds from) Short-term Investments 9 month as first filed | Payments for (Proceeds from) Short-term Investments 12 month | Payments for (Proceeds from) Short-term Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $112.20M 8-K · filed 2019-10-24 | ||||||
| 2017-12-31 | $3.39B 8-K · filed 2019-10-24 | ||||||
| 2016-12-31 | $1.33B 8-K · filed 2019-10-24 | ||||||
| 2015-12-31 | $842.20M 10-K · filed 2018-02-20 | ||||||
| 2014-12-31 | $1.64B 10-K · filed 2017-02-21 | ||||||
| 2013-12-31 | $1.53B 10-K · filed 2016-02-19 | ||||||
| 2012-12-31 | $2.43B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $2.78B derived: sum of 2 quarters · filed 2015-02-19 | $2.63B derived: sum of 3 quarters · filed 2015-02-19 | $2.17B 10-K · filed 2015-02-19 | -$375.10M 10-K · filed 2013-02-21 | ||
| 2012-09-30 | $351.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | $200.30M derived: sum of 2 quarters · filed 2012-10-26 | -$257.30M 10-Q · filed 2012-10-26 | $2.35B derived: sum of 4 quarters · filed 2014-02-19 | |||
| 2012-06-30 | -$151.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-27 | -$608.70M 10-Q · filed 2012-07-27 | $2.00B derived: sum of 3 quarters · filed 2014-02-19 | $1.97B derived: sum of 4 quarters · filed 2014-02-19 | |||
| 2012-03-31 | -$457.60M 10-Q · filed 2012-04-30 | $2.15B derived: sum of 2 quarters · filed 2014-02-19 | $2.12B derived: sum of 3 quarters · filed 2014-02-19 | $2.14B derived: sum of 4 quarters · filed 2014-02-19 | |||
| 2011-12-31 | $2.60B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $2.58B derived: sum of 2 quarters · filed 2014-02-19 | $2.60B derived: sum of 3 quarters · filed 2014-02-19 | $2.06B 10-K · filed 2014-02-19 | $250.90M 10-K · filed 2012-02-24 | ||
| 2011-09-30 | -$26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | -$6.00M derived: sum of 2 quarters · filed 2012-10-26 | -$545.00M 10-Q · filed 2012-10-26 | -$59.10M derived: sum of 4 quarters · filed 2013-02-21 | |||
| 2011-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-27 | -$519.00M 10-Q · filed 2012-07-27 | -$33.10M derived: sum of 3 quarters · filed 2013-02-21 | $164.90M derived: sum of 4 quarters · filed 2013-02-21 | |||
| 2011-03-31 | -$539.00M 10-Q · filed 2012-04-30 | -$53.10M derived: sum of 2 quarters · filed 2013-02-21 | $144.90M derived: sum of 3 quarters · filed 2013-02-21 | $146.70M derived: sum of 4 quarters · filed 2013-02-21 | |||
| 2010-12-31 | $485.90M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $683.90M derived: sum of 2 quarters · filed 2013-02-21 | $685.70M derived: sum of 3 quarters · filed 2013-02-21 | $686.50M 10-K · filed 2013-02-21 | |||
| 2010-09-30 | $198.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $199.80M derived: sum of 2 quarters · filed 2011-10-28 | $200.60M 10-Q · filed 2011-10-28 | $364.70M derived: sum of 4 quarters · filed 2012-02-24 | |||
| 2010-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-29 | $2.60M 10-Q · filed 2011-07-29 | $166.70M derived: sum of 3 quarters · filed 2012-02-24 | $61.30M derived: sum of 4 quarters · filed 2012-02-24 | |||
| 2010-03-31 | $800.00K 10-Q · filed 2011-04-29 | $164.90M derived: sum of 2 quarters · filed 2012-02-24 | $59.50M derived: sum of 3 quarters · filed 2012-02-24 | -$112.10M derived: sum of 4 quarters · filed 2012-02-24 | |||
| 2009-12-31 | $164.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $58.70M derived: sum of 2 quarters · filed 2012-02-24 | -$112.90M derived: sum of 3 quarters · filed 2012-02-24 | -$399.10M 10-K · filed 2012-02-24 | |||
| 2009-09-30 | -$105.40M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2010-10-29 | -$277.00M derived: sum of 2 quarters · filed 2010-10-29 | -$563.20M 10-Q · filed 2010-10-29 | $563.20M 10-Q · filed 2009-10-30 | -$1.28B derived: sum of 4 quarters · filed 2011-02-22 | ||
| 2009-06-30 | -$171.60M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2010-08-02 | -$457.80M 10-Q/A · filed 2010-08-02 | $457.80M 10-Q · filed 2009-07-31 | -$1.18B derived: sum of 3 quarters · filed 2011-02-22 | -$684.70M derived: sum of 4 quarters · filed 2011-02-22 | ||
| 2009-03-31 | -$286.20M 10-Q · filed 2010-07-30 | -$1.01B derived: sum of 2 quarters · filed 2011-02-22 | -$513.10M derived: sum of 3 quarters · filed 2011-02-22 | ||||
| 2008-12-31 | -$720.30M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | -$226.90M derived: sum of 2 quarters · filed 2011-02-22 | -$957.60M 10-K · filed 2011-02-22 | ||||
| 2008-09-30 | $493.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-30 | -$237.30M 10-Q · filed 2009-10-30 | |||||
| 2008-06-30 | -$730.70M 10-Q · filed 2009-07-31 | ||||||
| 2007-12-31 | $376.90M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |